Cargando…
Role of PAI-1 in hepatic steatosis and dyslipidemia
Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension and insulin resistance. Here we show that PAI-1 is also a cri...
Autores principales: | Levine, Joshua A., Oleaga, Carlota, Eren, Mesut, Amaral, Ansel P., Shang, Meng, Lux, Elizabeth, Khan, Sadiya S., Shah, Sanjiv J., Omura, Yasuhiro, Pamir, Nathalie, Hay, Joshua, Barish, Grant, Miyata, Toshio, Tavori, Hagai, Fazio, Sergio, Vaughan, Douglas E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801442/ https://www.ncbi.nlm.nih.gov/pubmed/33432099 http://dx.doi.org/10.1038/s41598-020-79948-x |
Ejemplares similares
-
OR22-6 Reversal Of Diet Induced Metabolic Syndrome In Mice With An Orally Active Small Molecule Inhibitor Of PAI-1
por: Levine, Joshua, et al.
Publicado: (2019) -
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020) -
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
por: Oleaga, Carlota, et al.
Publicado: (2021) -
PAI-1 is a critical regulator of FGF23 homeostasis
por: Eren, Mesut, et al.
Publicado: (2017) -
Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM(2.5)()
por: Ghosh, Asish K., et al.
Publicado: (2021)